Non-Small Cell Lung Cancer

Latest News

Advances in Oncology: When Innovation and Challenge Intersect
Advances in Oncology: When Innovation and Challenge Intersect

August 21st 2025

Precision oncology's promise was the key theme of the July 17 session of the Institute for Value-Based Medicine with faculty from multiple institutions in the Boston, Massachusetts area.

For Better Cancer Outcomes, It’s All About Access
For Better Cancer Outcomes, It’s All About Access

August 21st 2025

The Future of Oncology Is Driving Value, Access, Innovation From Inpatient to Outpatient Care
The Future of Oncology Is Driving Value, Access, Innovation From Inpatient to Outpatient Care

August 21st 2025

Lung cancer | Image credit: steph photographies - stock.adobe.com
Salvage Surgery a Possible Approach in NSCLC After Immunotherapy

August 15th 2025

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com
Predictive Model Forecasts Advanced NSCLC Outcomes

August 14th 2025

Advancing ALK+ NSCLC Care: Optimizing Treatment, Sequencing, and Long-Term Outcomes

Get insight to advances in ALK+ NSCLC treatment, including long-term lorlatinib data, new therapy approvals, brain metastasis management, and evolving sequencing strategies with this series.

AJMC Peer Exchange logo
Continuing Medical Education
View All
August 26th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 26th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Jessica K. Paulus, ScD, Ontada
Published: July 6th 2024 | Updated: July 1st 2024

COVID-19's Potential Impact on Advanced-Stage Lung Cancer Trends

Maggie L. Shaw
In our ongoing interview with Jessica K. Paulus, ScD, Ontada, she explains potential drivers behind changing trends in care for lung cancer that may have been influenced by the COVID-19 pandemic.
Comparative analysis |Image Credit: teguhjatipras-stock.adobe.com
July 3rd 2024

Sotorasib Cost-Effective in US, Not in China for NSCLC

Maggie L. Shaw
Investigators compared cost-effectiveness of the KRAS inhibitor sotorasib against the taxane docetaxel in the second line for non–small cell lung cancer (NSCLC).
essica K. Paulus, ScD, Ontada
June 28th 2024

Real-World Challenges in Cancer Screening: Understanding Data Sources

Maggie L. Shaw
In part 3 of our interview, Jessica K. Paulus, ScD, Ontada, addresses the importance of understanding data sources and their impact on clinical research.
FDA building sign | Image credit: Tada Images – stock.adobe.com
June 27th 2024

FDA Issues CRL for Patritumab Deruxtecan for Locally Advanced, Metastatic EGFR-Mutated NSCLC

Hayden E. Klein
The complete response letter (CRL) was not related to safety or efficacy data, but was a result of inspection findings at a third-party manufacturing facility.
Interview with Jessica K. Paulus, ScD, Ontada
June 22nd 2024

Dr Jessica Paulus: Despite Treatment Advances, Progress in Lung Cancer Will Continue to Take Time

Maggie L. Shaw
“The screening victory there is going to take some more time to show its benefit at the population level,” notes Jessica K. Paulus, ScD. “Some of these things are just going to be reductions in mortality that we have to wait to observe over time.”
image of lung cancer | Image Credit: laszlo-stock.adobe.com
June 21st 2024

Early Detection of PH May Be Key to Improving NSCLC Survival Rates

Maggie L. Shaw
This investigation sought to expand knowledge of the impact of comorbid pulmonary hypertension (PH) on diagnosed non–small cell lung cancer (NSCLC), using data from adult patients treated at military hospital facilities within the US.
Medical Illustration showing lung cancer | Image Credit: Crystallight-stock.adobe.com
June 18th 2024

Second Analysis of FLAURA2 Trial Extends Benefit of Osimertinib Combo in NSCLC

Tony Berberabe, MPH
Encouraging trends were seen with osimertinib and platinum-pemetrexed chemotherapy in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) in the phase 3 FLAURA2 study.
Jessica K. Paulus, ScD, Ontada
June 14th 2024

Ontada’s Dr Jessica Paulus on Investigating Secular Trends in Presenting Lung Cancer Stage

Maggie L. Shaw
This investigation used data from The US Oncology Network on trends in lung cancer stage when patients present for care.
Human lungs with cancer cells| Image Credit: Rasi-stock.adobe.com
June 12th 2024

TRITON Study to Target Biomarkers for Patients With Select NSCLC Mutations

Maggie L. Shaw
The TRITON study is evaluating tremelimumab/durvalumab/chemotherapy vs pembrolizumab/chemotherapy in non–small lung cancer (NSCLC) with STK11 and/or KEAP1 and/or KRAS mutations.
Lung CT | Image Credit: Markoff-stock.adobe.com
June 5th 2024

Broader Studies Needed on Lung Cancer Biopsy Decisions

Maggie L. Shaw
This investigation sprung from a lack of current knowledge on the impact of nonmalignant results following thoracic surgery for lung cancer, according to the authors.
Lung cancer | Image Credit: WrightStudio-stock.adobe.com
May 31st 2024

Awareness and Cost Hinder Lung Cancer Screening for Asian Americans

Maggie L. Shaw
Data presented at the recent American Thoracic Society 2024 international conference identified the top barriers to lung cancer screening in Asian Americans, and common risk factors among this population.
AJMC
May 31st 2024

Physician Preferences for an Electronic Lung Cancer Screening Decision Aid

Orly Morgan, BA Julie B. Schnur, PhD Michael A. Diefenbach, PhD Minal S. Kale, MD, MPH
This qualitative study on primary care physicians yielded suggestions that can inform the design of an effective lung cancer screening decision aid tool and implementation into the electronic health record.
Global currency | Image Credit: Panuwat-stock.adobe.com
May 30th 2024

Durvalumab's High Costs Hinder Global Uptake for Stage III NSCLC Maintenance Therapy

Maggie L. Shaw
This international study, incorporating data from the US, Brazil, Singapore, and Spain, shows that durvalumab as maintenance therapy for use against non–small cell lung cancer remains a cost-prohibitive treatment option.
Lung cancer awareness | Image Credit: WindyNight-stock.adobe.com
May 24th 2024

Body Composition Changes Linked to Poor NSCLC Outcomes

Maggie L. Shaw
For this analysis of how body composition might affect the impact of immunotherapy used to treat non–small cell lung cancer (NSCLC), investigators from Dana-Farber Brigham Cancer Center compared patient outcomes based on baseline body composition measurements or first follow-up scan.
EGFR mutation test | Image Credit: Saiful52-stock.adobe.com
May 21st 2024

ASCENT Trial: Optimizing TKI Therapy for EGFR-Mutant NSCLC Challenges

Maggie L. Shaw
Investigators continue to seek more information on how to optimally integrate treatment with tyrosine kinase inhibitors (TKIs) into an established concurrent chemoradiotherapy regimen.
KRAS mutation | Image Credit:InnovationCreation-stock.adobe.com
May 18th 2024

Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation

Maggie L. Shaw
Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Clinical research graphic | Image Credit: Karan - stock.adobe.com
May 8th 2024

Integrating RECIST and Clinician Approaches Boosts NSCLC Research

Maggie L. Shaw
Outcomes among patients with stage IV non–small cell lung cancer as evaluated within clinical trials via Response Evaluation Criteria in Solid Tumors (RECIST) and clinician response criteria in observational studies were compared for their concordance and reliability.
Magnified lung cancer | Image credit: Laszlo - stock.adobe.com
May 3rd 2024

Positive 5-Year Results for Gefitinib Combo in EGFR-Variant Lung Cancer

Luke Halpern
Consistent with previous observations, overall survival and progression-free survival remained strong at the follow-up point.
Oncologist examining lung cancer results | Image Credit: vladislav - stock.adobe.com
April 27th 2024

Durvalumab Confirmed Beneficial After NSCLC Chemoradiotherapy

Maggie L. Shaw
This analysis evaluated patient-related outcomes between those who did and did not receive consolidation durvalumab after chemoradiotherapy for unresectable stage III non–small cell lung cancer.
Lung cancer concept | Image Credit: ivelinradkov - stock.adoe.com
April 24th 2024

Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC

Gayle Turim Dickstein
For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Lung cancer concept | Image Credit: DraganaGordic - stock.adobe.com
April 20th 2024

Alectinib Significantly Improves Disease-Free Survival in ALK-Positive NSCLC

Maggie L. Shaw
Seeking more data on adjuvant alectinib in patients who have resectable ALK-positive non–small cell lung cancer (NSCLC), investigators compared outcomes vs chemotherapy.
Shackled with bills | Image Credit: petrovk - stock.adobe.com
April 17th 2024

Financial Strain, Quality of Life Top Unmet Needs in Lung Cancer Survivors

Maggie L. Shaw
The data for this analysis on survivors of lung cancer came from Johns Hopkins Sidney Kimmel Comprehensive Cancer Center thoracic oncology clinics.
Lung cancer in black marker | Image Credit: MPStudio - stock.adobe.com
April 11th 2024

Expert Analysis Reveals Critical Insights for Optimizing Care in LA-NSCLC

Maggie L. Shaw
Authors conducted a systematic literature review to gather evidence on the appropriateness of recommended treatments for locally advanced non–small cell lung cancer (LA-NSCLC) from the American Radium Society Appropriate Use Criteria Thoracic Committee.
Intravenous drip in the pole against the bright light | Image Credit: sudok1 - stock.adobe.com
April 9th 2024

Neoadjuvant Chemoimmunotherapy Shows Superiority in Non–Small Cell Lung Cancer Treatment

Giuliana Grossi
The study compared the adverse events and surgical, pathological, and efficacy outcomes associated with neoadjuvant chemoimmunotherapy vs chemotherapy, particularly focusing on patients with PD-L1 levels less than 1%.
Medical doctor drawing lung cancer on the virtual screen | Image Credit: WrightStudio - stock.adobe.com
April 2nd 2024

Navigating Complexity: Understanding Variations in Lung Cancer Screening Decision-Making

Maggie L. Shaw
This analysis found the complex decision-making process of lung cancer screening among eligible individuals is infused with 3 principal themes that may influence how primary care physicians approach patients with comorbidities.
Wearable tech activity tracker | Image Credit: Orxan - stock.adobe.com
March 28th 2024

Wearable Activity Tracker Data Enhance Patient Assessment in Lung Cancer

Maggie L. Shaw
This analysis included 119 patients with advanced lung cancer, who were evaluated on 3 facets of physical activity over 14 days of using the amuelink wearable device from Sony: metabolic equivalent tasks, distance walked, and steps taken.
Gene expression profiling on blue backgound | Image Credit: dariaren - stock.adobe.com
March 23rd 2024

Experts Sound the Alarm on Lack of Comprehensive Genomic Profiling in NSCLC

Maggie L. Shaw
Investigators examined the downstream effect of single-gene testing for guideline-recommended biomarkers on comprehensive genomic profiling in non–small cell lung cancer (NSCLC).
A lung specialist | Image Credit: mi_viri - srock.adobe.com
March 21st 2024

Low Screening Rates for Lung Cancer Highlight Public Health Priority

Maggie L. Shaw
Overall rates for lung cancer screening remain low, despite the US Preventive Services Task Force revising its annual screening recommendation in 2021 by lowering the age of initial screening for current or former smokers and their pack-year history.
Doctor lung cancer tablet | Image Credit: © steph photographies - stock.adobe.com
March 15th 2024

ctDNA Holds Potential to Guide Management of EGFR-Mutated NSCLC

Christina Mattina
A review explores the evidence supporting the use of circulating tumor DNA (ctDNA) liquid biopsies to help direct the evaluation and management of EGFR-mutated non–small cell lung cancer (NSCLC), including for assessing resistance to certain treatment options.
Joshua K. Sabari, MD, NYU Langone Perlmutter Cancer Center
March 14th 2024

Dr Joshua Sabari Looks to the Future of Targeted Treatment for NSCLC

Maggie L. Shaw
March 1 saw the FDA grant full approval to amivantamab plus chemotherapy for first-line use in patients who have non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, converting the May 2021 accelerated approval for this treatment in the second line.
<123456>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo